Clinical research organisation Chiltern International has launched its new website at www.chiltern.com which offers an updated modern look whilst providing enhanced user-friendly navigation and search facilities throughout the site.
Clinical research organisation Chiltern International has launched its new website at www.chiltern.com which offers an updated modern look whilst providing enhanced user-friendly navigation and search facilities throughout the site.
The website lists the company's expanding range of services, the latest company news, articles and PR updates. The last few years have been an exciting time for the company, with its achievements being reflected in the business awards it has won and the media coverage that has followed. In 2004, Chiltern International's success was recognised in the UK Thames Valley Fast 30 company listings of The Business Magazine and in 2003 it was announced as one of the winners of the Deloitte & Touche Indy 100 competition for the UK's fastest growing companies.
A major part of the new site is the Careers section, which will enable candidates to easily carry out job searches on a global basis, find out about training and take advantage of the candidate referral bonus scheme! Also improved functionality now means that candidates can easily register for the Job Alert service where their details are compared to any new job on the database and an automatic e-mail is sent when there are matching jobs.
The new site also features a specialized Volunteer/Patient section where users can learn about current clinical trials being carried out by the company. Volunteers play an important role in ensuring that new treatments are continually developed for the treatment of disease and Chiltern has a reputation for carrying out high quality clinical research.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.